Trademarkia Logo

Canada

C$
Trademark Search in Canada
KORRO BIO

View On IC.GC.CA

KORRO BIO
FORMALIZED

on 19 Aug 2024

Last Applicant/ Owned by

KORRO BIO INC.

One Kendall Square, Building 600Suite 6-401Cambridge, MA 02139

US

Serial Number

2344594 filed on 19th Aug 2024

Correspondent Address

ROBIC AGENCE PI S.E.C./ ROBIC IP AGENCY LP

630, boul. René-Lévesque Ouest20e étageMontréal

QUÉBEC

CA

H3B1S6

KORRO BIO

Trademark usage description

pharmaceutical preparations for the treatment of rare genetic diseases; pharmaceutical preparations containing biomedical compounds comprised of nucle Read More

Classification Information

Class [005]
Pharmaceutical preparations for the treatment of rare genetic diseases; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceutical preparations containing biomedical compounds comprised of ribonucleic acid polymers for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for use in RNA editing; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for use in base editing; Pharmaceutical preparations containing biomedical compounds comprised of nucleotide polymers for use as RNA therapeutic for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Pharmaceuticals, namely, bio-pharmaceutical preparations for the treatment of rare diseases

Classification kind code

12

Class [040]
Custom manufacture of biomedical compounds comprised of nucleotide polymers or biomedical compounds comprised of ribonucleic acid polymers for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders

Classification kind code

12

Class [042]
Pharmaceutical research and development; Pharmaceutical research and development in the fields of gene therapies, gene editing, drug discovery and development; Research and development of pharmaceutical products; Research and development in the field of bioscience; Research and development of biomedical compounds comprised of nucleotide polymers for use in targeted pharmaceutical therapies for the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders; Research and development of pharmaceutical preparations for the treatment of liver-based disorders, eye disorders and CNS disorders; Research and development of biomedical compounds comprised of nucleotide polymers for targeted RNA editing; Research and development of oligonucleotide drug platforms for use in the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders

Classification kind code

12

Mark Details

Serial Number

2344594

Mark Type

Trademark

Legal History

Action TakenStatus
Submitted for opposition 287
on 29th Aug 2024		Pre-Assessment Letter Sent
Submitted for opposition 30
on 19th Aug 2024		Filed
Submitted for opposition 1
on 19th Aug 2024		Created
Submitted for opposition 31
on 19th Aug 2024		Formalized